2022
DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice
Doyle EA, Weinzimer SA, Tamborlane W. DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice. The Science Of Diabetes Self-Management And Care 2022, 48: 476-482. PMID: 36129121, DOI: 10.1177/26350106221125699.Peer-Reviewed Original ResearchConceptsContinuous glucose monitorHigher A1C levelsA1c levelsDKA eventsInsulin pumpPump usersPump-treated patientsRetrospective chart reviewPediatric endocrinology practiceType 1 diabetesInsulin pump usersConcurrent illnessDKA preventionPump patientsDiabetes durationDKA episodesMean A1CChart reviewEndocrinology practiceDKA ratesDKA severityMean ageInsulin omissionMost episodesPatientsEfficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnel
2021
Racial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC).
Bacha F, Cheng P, Gal RL, Beaulieu LC, Kollman C, Adolph A, Shoemaker AH, Wolf R, Klingensmith GJ, Tamborlane WV. Racial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC). Diabetes Care 2021, 44: 2245-2251. PMID: 34475033, DOI: 10.2337/dc21-0143.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseType 2 diabetesNon-Hispanic blacksPediatric Diabetes ConsortiumFatty liver diseaseWorse metabolic controlRacial-ethnic disparitiesNon-Hispanic white youthManagement of youthSubsequent comorbiditiesDiabetic ketoacidosisInitial presentationLiver diseaseMean ageRegistry participantsMedical recordsC-peptideClinical dataDiabetesMetabolic controlHealth outcomesRacial-ethnic differencesEthnic disparitiesComorbiditiesRacial-ethnic groups
2018
Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
Laffel LMB, Tamborlane WV, Yver A, Simons G, Wu J, Nock V, Hobson D, Hughan KS, Kaspers S, Marquard J. Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Diabetic Medicine 2018, 35: 1096-1104. PMID: 29655290, PMCID: PMC6099360, DOI: 10.1111/dme.13629.Peer-Reviewed Original ResearchConceptsType 2 diabetesG/24 hPharmacodynamic profileType 2Type 2 diabetes trialsSodium-glucose co-transporter-2 inhibitor empagliflozinMaximum observed plasma concentrationPlasma concentration-time curveSimilar exposure-response relationshipsDoses of empagliflozinSerious adverse eventsParallel-group studyUrinary glucose excretionSingle oral doseDrug-related eventsObserved plasma concentrationConcentration-time curveExposure-response relationshipAdjusted mean increaseAdverse eventsDiabetes (ACCORD) trialGlucose excretionInhibitor empagliflozinOral doseMean age
2015
Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium
Klingensmith GJ, Connor CG, Ruedy KJ, Beck RW, Kollman C, Haro H, Wood JR, Lee JM, Willi SM, Cengiz E, Tamborlane WV, Consortium F. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. Pediatric Diabetes 2015, 17: 266-273. PMID: 25951940, DOI: 10.1111/pedi.12281.Peer-Reviewed Original ResearchConceptsHyperglycemic hyperosmolar stateType 2 diabetesDiabetic ketoacidosisMedian body mass index (BMI) z-scoreBody mass index z-scorePediatric Diabetes ConsortiumPediatric diabetes centersTime of diagnosisIndex z-scoreSymptoms of diabetesHigh-risk childrenYr of ageCombination of insulinT2D participantsLifestyle modificationHyperosmolar stateLaboratory characteristicsClinical presentationDiabetes CenterInitial treatmentClinic registryMean ageFamily historyPediatric diseasesDiabetes
2012
Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat in Youth
Klingensmith GJ, Tamborlane WV, Wood J, Haller MJ, Silverstein J, Cengiz E, Shanmugham S, Kollman C, Wong-Jacobson S, Beck RW, Consortium P. Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat in Youth. The Journal Of Pediatrics 2012, 162: 330-334.e1. PMID: 22901739, DOI: 10.1016/j.jpeds.2012.06.058.Peer-Reviewed Original ResearchConceptsSevere diabetic ketoacidosisDiabetic ketoacidosisHemoglobin A1cIncidence of DKAInitial hemoglobin A1cNew-onset T1DPediatric Diabetes ConsortiumDiabetes-associated autoantibodiesLife-threatening complicationsOnset of T1DAfrican American raceType 1 diabetesNon-Hispanic CaucasiansClinical characteristicsEligible subjectsDiabetes onsetMean ageFamily historyPrivate health insuranceInclusion criteriaT1DMultivariate analysisYounger ageDemographic informationHealth insurance